Literature DB >> 19846955

Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma.

Yun Yen1, Samuel So, Michal Rose, M Wasif Saif, Edward Chu, Shwu-Huey Liu, Angeline Foo, Zaoli Jiang, Tahmun Su, Yung-Chi Cheng.   

Abstract

PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (16.5 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19846955

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  31 in total

Review 1.  Cancer Biomarkers for Integrative Oncology.

Authors:  Aniruddha Ganguly; David Frank; Nagi Kumar; Yung-Chi Cheng; Edward Chu
Journal:  Curr Oncol Rep       Date:  2019-03-05       Impact factor: 5.075

2.  Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS).

Authors:  Wei Zhang; Muhammad W Saif; Ginger E Dutschman; Xin Li; Wing Lam; Scott Bussom; Zaoli Jiang; Min Ye; Edward Chu; Yung-Chi Cheng
Journal:  J Chromatogr A       Date:  2010-07-21       Impact factor: 4.759

Review 3.  Herbal traditional Chinese medicine and its evidence base in gastrointestinal disorders.

Authors:  Rolf Teschke; Albrecht Wolff; Christian Frenzel; Axel Eickhoff; Johannes Schulze
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

Review 4.  Safety surveillance of traditional Chinese medicine: current and future.

Authors:  Shwu-Huey Liu; Wu-Chang Chuang; Wing Lam; Zaoli Jiang; Yung-Chi Cheng
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

5.  First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.

Authors:  Muhammad Wasif Saif; Jia Li; Lynne Lamb; Kristin Kaley; Kyle Elligers; Zaoli Jiang; Scott Bussom; Shwu-Huey Liu; Yung-Chi Cheng
Journal:  Cancer Chemother Pharmacol       Date:  2013-12-03       Impact factor: 3.333

6.  Preclinical studies of the Chinese Herbal Medicine formulation PHY906 (KD018) as a potential adjunct to radiation therapy.

Authors:  Sara Rockwell; Tina A Grove; Yanfeng Liu; Yung-Chi Cheng; Susan A Higgins; Carmen J Booth
Journal:  Int J Radiat Biol       Date:  2012-09-03       Impact factor: 2.694

Review 7.  Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.

Authors:  Xiang-Yuan Luo; Kong-Ming Wu; Xing-Xing He
Journal:  J Exp Clin Cancer Res       Date:  2021-05-18

8.  Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment.

Authors:  Ena Wang; Scott Bussom; Jinguo Chen; Courtney Quinn; Davide Bedognetti; Wing Lam; Fulan Guan; Zaoli Jiang; Yichao Mark; Yingdong Zhao; David F Stroncek; Jeffrey White; Francesco M Marincola; Yung-Chi Cheng
Journal:  BMC Med Genomics       Date:  2011-05-11       Impact factor: 3.063

9.  Anticancer activity of an extract from needles and twigs of Taxus cuspidata and its synergistic effect as a cocktail with 5-fluorouracil.

Authors:  Weihu Shang; Jinping Qiao; Chenxin Gu; Wei Yin; Jinglei Du; Wei Wang; Meilin Zhu; Mei Han; Weidong Lu
Journal:  BMC Complement Altern Med       Date:  2011-12-02       Impact factor: 3.659

10.  Lessons learnt from evidence-based approach of using chinese herbal medicines in liver cancer.

Authors:  Zhan Zheng; William Chi-Shing Cho; Ling Xu; Juyong Wang; Daniel Man-Yuen Sze
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-29       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.